PrimeC
Amyotrophic Lateral Sclerosis (ALS)
Key Facts
About NeuroSense Therapeutics
NeuroSense Therapeutics is an Israeli, NASDAQ-listed biotech focused on developing treatments for neurodegenerative diseases, with Amyotrophic Lateral Sclerosis (ALS) as its lead indication. The company's core strategy involves targeting multiple disease pathways concurrently with its fixed-dose combination drug, PrimeC, which is in a Phase IIb clinical trial (PARADIGM). NeuroSense employs biomarker analyses to demonstrate target engagement and guide development. As a micro-cap company, it represents a high-risk, high-reward opportunity contingent on the success of its lead program in a challenging therapeutic area.
View full company profileAbout NeuroSense Therapeutics
NeuroSense Therapeutics is an Israeli, NASDAQ-listed biotech focused on developing treatments for neurodegenerative diseases, with Amyotrophic Lateral Sclerosis (ALS) as its lead indication. The company's core strategy involves targeting multiple disease pathways concurrently with its fixed-dose combination drug, PrimeC, which is in a Phase IIb clinical trial (PARADIGM). NeuroSense employs biomarker analyses to demonstrate target engagement and guide development. As a micro-cap company, it represents a high-risk, high-reward opportunity contingent on the success of its lead program in a challenging therapeutic area.
View full company profileTherapeutic Areas
Other Amyotrophic Lateral Sclerosis (ALS) Drugs
| Drug | Company | Phase |
|---|---|---|
| NPT520-34 | Neuropore Therapies | Pre-clinical/Phase 1 |
| NUZ-001 | Neurizon Therapeutics | Phase 2/3 (Platform Trial) |
| CNM-Au8 | Clene | Phase 2/3 |
| Masitinib | AB Science | Phase 3 |
| Undisclosed Program | Zhimeng Biopharma | Clinical |
| SLS-005 | Seelos Therapeutics | Platform Trial |
| PMN442 | ProMIS Neurosciences | Preclinical |
| nAV-101 | nVector | Pre-clinical |
| ALTA-808 | Alteron Therapeutics | Preclinical |
| GM6 | Genervon Biopharmaceuticals | Phase 2 |
| Lou Gehrig’s disease | Genclis | Discovery |
| Treg-directed therapy for ALS | Iltoo Pharma | Pre-clinical |